![Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation | British Journal of Cancer Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-019-0477-7/MediaObjects/41416_2019_477_Fig1_HTML.png)
Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation | British Journal of Cancer
![K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways - Journal of Thoracic Oncology K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4c1f1d79-3e74-4260-8673-db7d8f6ccf37/gr1_lrg.jpg)
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways - Journal of Thoracic Oncology
![KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS - ScienceDirect KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0092867417315003-fx1.jpg)
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS - ScienceDirect
![The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors | Nature Communications The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-26526-y/MediaObjects/41467_2021_26526_Fig1_HTML.png)
The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors | Nature Communications
Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations | Journal of Proteome Research
![Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer | PNAS Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer | PNAS](https://www.pnas.org/cms/10.1073/pnas.2016904118/asset/747374a3-fd8e-48c5-8fb5-b983e9f71c51/assets/images/large/pnas.2016904118fig05.jpg)
Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer | PNAS
![Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics - ScienceDirect Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2211124720303284-fx1.jpg)
Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics - ScienceDirect
![Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11 - Lung Cancer Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11 - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/73e33f9e-d5e4-4fba-8f34-b867fce145f4/gr1_lrg.jpg)
Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11 - Lung Cancer
![KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry - ScienceDirect KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0969212617302186-fx1.jpg)